{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:55Z","timestamp":1791559435478,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"DOI":"10.1007\/s43440-026-00906-x","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:51Z","timestamp":1790237391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gastrointestinal adverse events associated with axitinib: pharmacovigilance analysis of the Japanese adverse drug event report database"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8882-8846","authenticated-orcid":false,"given":"Keiko","family":"Hosohata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-2293","authenticated-orcid":false,"given":"Yuko","family":"Kanbayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"906_CR1","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM, O\u2019Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610\u201321. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17016557.","journal-title":"J Clin Invest"},{"key":"906_CR2","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272\u201383. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19010843.","journal-title":"Clin Cancer Res"},{"key":"906_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2013.145","volume":"108","author":"D Cella","year":"2013","unstructured":"Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer. 2013;108:1571\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23579211.","journal-title":"Br J Cancer"},{"key":"906_CR4","doi-asserted-by":"crossref","unstructured":"Ritter K, Strojny M, McCullough J, Law J. Real-world efficacy and tolerability of axitinib\u2009+\u2009pembrolizumab in the treatment of renal cell carcinoma. J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners. Published online May 5, 2025:10781552251331576. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40325928","DOI":"10.1177\/10781552251331576"},{"key":"906_CR5","doi-asserted-by":"publisher","first-page":"1585862","DOI":"10.3389\/fphar.2025.1585862","volume":"16","author":"L Li","year":"2025","unstructured":"Li L, Bai J, Wen X, Zeng X. Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database. Front Pharmacol. 2025;16:1585862. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40331199.","journal-title":"Front Pharmacol"},{"key":"906_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/TCRM.S176620","volume":"15","author":"A Inada","year":"2019","unstructured":"Inada A, Hosohata K, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, et al. Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Ther Clin Risk Manag. 2019;15:59\u201364. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30636879.","journal-title":"Ther Clin Risk Manag"},{"key":"906_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40261-019-00788-3","volume":"39","author":"K Hosohata","year":"2019","unstructured":"Hosohata K, Oyama S, Niinomi I, Wakabayashi T, Inada A, Iwanaga K. Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database. Clin Drug Investig. 2019;39:665\u201370. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31054085.","journal-title":"Clin Drug Investig"},{"key":"906_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5414\/CP203724","volume":"58","author":"I Niinomi","year":"2020","unstructured":"Niinomi I, Hosohata K, Oyama S, Inada A, Hirai T, Iwanaga K. Drug-induced thrombotic microangiopathy using the Japanese pharmacovigilance database. Int J Clin Pharmacol Ther. 2020;58:543\u201349. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32631486.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"906_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.31083\/ph.2020.9189","volume":"75","author":"I Niinomi","year":"2020","unstructured":"Niinomi I, Hosohata K, Oyama S, Inada A, Wakabayashi T, Iwanaga K. Evaluation of adverse events associated with filgrastim originator and biosimilar using a spontaneous reporting system database. Pharmazie. 2020;75:151\u201353. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32295692.","journal-title":"Pharmazie"},{"key":"906_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5414\/CP203898","volume":"59","author":"T Wakabayashi","year":"2021","unstructured":"Wakabayashi T, Ueno S, Nakatsuji T, Hirai T, Niinomi I, Oyama S, et al. Safety profiles of new xanthine oxidase inhibitors: A post-marketing study. Int J Clin Pharmacol Ther. 2021;59:372\u201377. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33560211.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"906_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.5414\/CP204016","volume":"59","author":"H Kambara","year":"2021","unstructured":"Kambara H, Oyama S, Inada A, Niinomi I, Wakabayashi T, Hosohata K. Current status of adverse event profile of tacrolimus in patients with solid organ transplantation from a pharmacovigilance study. Int J Clin Pharmacol Ther. 2021;59:753\u201359. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34402788.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"906_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/VHRM.S482190","volume":"20","author":"M Kozaru","year":"2024","unstructured":"Kozaru M, Kambara H, Higuchi A, Kagatsume T, Hosohata K. Association of Clopidogrel with Interstitial Lung Disease: Gaining Insight Through the Japanese Pharmacovigilance Database. Vasc Health Risk Manag. 2024;20:415\u201320. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39247557.","journal-title":"Vasc Health Risk Manag"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.2147\/OPTH.S439255","volume":"17","author":"M Kozaru","year":"2023","unstructured":"Kozaru M, Iida T, Hosohata K. A Pharmacovigilance Study of Drug-Induced Glaucoma Utilizing the Japanese Adverse Event Reporting System. Clin Ophthalmol. 2023;17:3645\u201353. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38050555.","journal-title":"Clin Ophthalmol"},{"key":"906_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40261-025-01490-3","volume":"45","author":"Y Kanbayashi","year":"2025","unstructured":"Kanbayashi Y, Morioka R, Hosohata K. Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database. Clin Drug Investig. 2025;45:901\u201307. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/41060507.","journal-title":"Clin Drug Investig"},{"key":"906_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11998548.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"906_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23673816.","journal-title":"Drug Saf"},{"key":"906_CR17","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/j.clgc.2021.03.019","volume":"19","author":"BI Rini","year":"2021","unstructured":"Rini BI, Atkins MB, Choueiri TK, Thomaidou D, Rosbrook B, Thakur M, et al. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2021;19:e306\u201312. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33947608.","journal-title":"Clin Genitourin Cancer"},{"key":"906_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Soulieres D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563\u201373. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33284113.","journal-title":"Lancet Oncol"},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2217\/fon-2018-0442","volume":"15","author":"X Sheng","year":"2019","unstructured":"Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, et al. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncol. 2019;15:53\u201363. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30058839.","journal-title":"Future Oncol"},{"key":"906_CR20","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1093\/annonc\/mdv388","volume":"26","author":"YK Kang","year":"2015","unstructured":"Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, et al. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Annals oncology: official J Eur Soc Med Oncol. 2015;26:2457\u201363. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26386123.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"906_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/CAD.0000000000000742","volume":"30","author":"O Nigro","year":"2019","unstructured":"Nigro O, Pastore A, Tartaro T, Bolzacchini E, Tuzi A, Pinotti G. Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature. Anticancer Drugs. 2019;30:425\u201327. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30640790.","journal-title":"Anticancer Drugs"},{"key":"906_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.critrevonc.2013.10.002","volume":"89","author":"WX Qi","year":"2014","unstructured":"Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2014;89:394\u2013403. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24182420.","journal-title":"Crit Rev Oncol Hematol"},{"key":"906_CR23","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-11-0534","volume":"17","author":"J Fruehauf","year":"2011","unstructured":"Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011;17:7462\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21976544.","journal-title":"Clin Cancer Res"},{"key":"906_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1634\/theoncologist.2010-0271","volume":"16","author":"D Keefe","year":"2011","unstructured":"Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011;16:432\u201344. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21441297.","journal-title":"Oncologist"},{"key":"906_CR25","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41416-023-02416-6","volume":"129","author":"PJ Woll","year":"2023","unstructured":"Woll PJ, Gaunt P, Gaskell C, Young R, Benson C, Judson IR, et al. Axitinib in patients with advanced\/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata. Br J Cancer. 2023;129:1490\u201399. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37684354.","journal-title":"Br J Cancer"},{"key":"906_CR26","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.urology.2016.12.035","volume":"101","author":"T Kameda","year":"2017","unstructured":"Kameda T, Nakano K, Yamazaki M, Koshimizu T, Morita T. Axitinib-induced Pneumatosis Intestinalis and Acute Acalculous Cholecystitis in a Patient With Renal Cell Carcinoma. Urology. 2017;101:e7\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28039049.","journal-title":"Urology"},{"key":"906_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","volume":"21","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Dai B, Zhang Q. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022;21:563\u201372. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34918584.","journal-title":"Expert Opin Drug Saf"},{"key":"906_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.euf.2022.07.003","volume":"9","author":"J Matsumoto","year":"2023","unstructured":"Matsumoto J, Iwata N, Watari S, Ushio S, Shiromizu S, Takeda T, et al. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System. Eur Urol Focus. 2023;9:141\u201344. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35915038.","journal-title":"Eur Urol Focus"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00906-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:53Z","timestamp":1790237393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00906-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":28,"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00906-x","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}